stockrowViridian Therapeutics, Inc.
VRDN Healthcare Biotechnology
Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024.
- Revenue
- −63.5%
- EPS
- −5.00%
- Free cash flow
- −9.92%
- Total debt
- +1,064.9%
Quarter to September 2026, against a year earlier
Follow VRDN
Alert me
Viridian Therapeutics, Inc. (VRDN) Total debt
Viridian Therapeutics, Inc.'s total debt at the end of fiscal 2025 was $49.9M, up 142.6% from $20.6M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $242.2M. Over the past ten years it has ranged from $43.0K (fiscal 2020) to $49.9M (fiscal 2025) — the current reading is the highest in ten years. Viridian Therapeutics, Inc. ranks 51st of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $49.9M | 142.64% |
| FY2024 | $20.6M | 1.87% |
| FY2023 | $20.2M | 334.98% |
| FY2022 | $4.6M | 793.27% |
| FY2021 | $520.0K | 1,109.30% |
| FY2020 | $43.0K | (99.01%) |
| FY2019 | $4.3M | (45.93%) |
| FY2018 | $8.0M | (19.33%) |
| FY2017 | $9.9M | 251.84% |
| FY2016 | $2.8M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $242.2M | 380.13% |
| Mar 2026 | $50.4M | 0.99% |
| Dec 2025 | $49.9M | 139.06% |
| Sep 2025 | $20.9M | 0.49% |
| 37 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| CELC Celcuity, Inc. compare | $753.2M |
| TLX Telix Pharmaceuticals Limited compare | $575.9M |
| VKTX Viking Therapeutics, Inc. compare | $250.7M |
| VRDN Viridian Therapeutics, Inc. | $242.2M |
| DYN Dyne Therapeutics, Inc. compare | $213.5M |
| TARS Tarsus Pharmaceuticals, Inc. compare | $72.9M |
| DNLI Denali Therapeutics Inc. compare | $5.4M |
| IDYA IDEAYA Biosciences, Inc. compare | $2.1M |
| ELVN Enliven Therapeutics, Inc. compare | $445.0K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on VRDN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement